Estados Unidos · Plataformas y datos · MarketBeat
PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance Date

Resumen detallado
PTC Therapeutics (NASDAQ:PTCT) expects to provide 2027 sales guidance for its oral phenylketonuria treatment Sephience in January, as executives seek to convince investors that the drug’s strong first year of sales can be sustained. Speaking at the Jefferies Healthcare Conference in London, CEO Mat
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)



